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Background: The human papillomaviruses (HPV) are simple, nonenveloped, double-stranded
DNA viruses, which are responsible for an enormous global burden of genital disease. HPV
is associated with 500,000 new cases of cervical cancer and 250,000 cervical cancer deaths
worldwide each year. Oncogenic HPV types 16 and 18 are responsible for a majority of cervical
cancers and can also cause low- and high-grade cervical lesions (CIN 1, 2, 3) as well as high-grade
vulvar or vaginal intraepithelial neoplasia (VIN or VaIN 2/3). Nononcogenic types HPV 6 and 11
also contribute to the overall burden of HPV disease, giving rise to CIN 1, anogenital warts,
cutaneous lesions, and respiratory papillomatosis.
Perspectives: A substantial body of clinical evidence demonstrates the effectiveness of cyto-
logical screening in preventing cervical cancer, but these techniques have not eradicated the
disease and are not widely available in most developing countries. Furthermore, evaluation and
management of HPV-associated cytologic abnormalities is costly, drains health care resources,
and increases the risk for adverse pregnancy outcome.
Conclusions: Targeting cervical cancer through universal immunization with a quadrivalent HPV
6, 11, 16, 18 vaccine may herald the beginning of the end of this deadly disease and substantially
reduce the overall global burden of HPV-related genital diseases.
© 2007 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
Introduction
Throughout the world, human papillomavirus (HPV)-
associated disease is an immense public health burden.
At least 50% of men and women will acquire genital HPV
infection during their lifetime.1 HPV is associated not only
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with 500,000 new cases of cervical cancer and 250,000
associated cervical cancer deaths worldwide each year2
but also causes vulvar, vaginal, anal, and penile cancers3-7
as well as cervical, vulvar/vaginal precancerous lesions,
genital warts, and respiratory papillomatosis.8- 14 Most in-
dividuals are not aware that they are infected with HPV
because of its subclinical or asymptomatic presentation,
and, thus, the virus can be spread easily and unknowingly
during sexual foreplay or sexual intercourse.12,15,16
The purpose of this article is to review the structure,
types, and epidemiology of HPV, and provide some insight
into the global burden of HPV-related disease, especially
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cervical cancer, which continues to be a major threat to
women' s health despite the introduction of Papanicolau
(Pap) smear screening techniques more than 50 years ago.
Structure and types of HPV
Papillomaviruses, including human papilloma virus (HPV),
are nonenveloped, double-stranded DNA viruses. The
genome of HPV is small in size (8 kb) and encodes 8
genes. These genes code for 6 nonstructural early proteins
(E1, E2, E4, E5, E6, E7) and 2 structural or late proteins
(L1, L2). Of the more than 100 HPV types characterized,
roughly 40 types infect the human genital tract where
they can induce a wide range of clinical manifestations,
including cervical, vaginal, and vulvar intraepithelial neo-
plasias (CIN, VaIN, and VIN, respectively), and cancer of
the cervix, vagina, and vulva in women, as well as genital
warts (condylomata acuminata) in women and men.17- 20
Genital HPVs are categorized into high-risk and low-risk
types defined by the strength of epidemiologic evidence
linking them to development of cervical cancer. Analysis
of pooled case-control data of women in 9 countries with
confirmed squamous-cell cervical cancer identified 15 HPV
types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59,
68, 73, and 82) as high risk --- that is, they were strongly
related to precancer and cancer of the anogenital region.
An additional 3 types were identified as probably high risk
(26, 53, 66) and 12 types (6, 11, 40, 42, 43, 44, 54, 61, 70,
72, 81, and CP6108) as lower risk for cervical cancer.21
Considerable differences exist in HPV types detected in
healthy women from different geographic areas, as shown
by a pooled analysis of HPV prevalence surveys in women
without cervical cytological abnormalities in 11 countries
(Nigeria, India, Vietnam, Thailand, Korea, Colombia, Ar-
gentina, Chile, the Netherlands, Italy, and Spain).22 This
heterogeneity, whilst less than that observed for many
viral and bacterial diseases, may have important clinical
ramifications with respect to employing screening tests for
specific virus types and the potential impact of vaccines
on the incidence of HPV infection. However, strikingly,
Figure 1 Studies in the UK and US show rapid acquisition of HPV in young women after first intercourse. Reproduced with permission.29,32
when considering women with clinical lesions, the more
advanced the lesion the less heterogeneous is the type
distribution across countries.23- 25 Worldwide HPV 16 and 18
as a major cause of cervical cancer is remarkably consis-
tent, being found in 64---79% of cases of cervical cancer,
depending on the region.
Risk of acquiring HPV infection
HPV infection is frequently acquired in adolescents
and young adults within months after first sexual
intercourse.8,26- 29 Up to 80% of women will likely acquire
genital HPV infection by the age of 50.1,30
A strikingly high HPV DNA prevalence rate has recently
been demonstrated among young women in Helsinki, Fin-
land. One third of 1st year university students attending
a health clinic or visiting a general practitioner for health
examination tested positive for any HPV in vaginal or cervi-
cal samples.31 The cumulative incidence of first-time HPV
infection in a cohort of female university students in Wash-
ington State was also shown to be high.32 Of the women
who initiated sexual activity during the study, first-time
HPV infection occurred in 32.3% after 24 months (Figure 1).
Additional evidence of rapid acquisition of HPV comes from
a study of UK adolescents (15---19 years of age, who had
had only one sexual partner).29 This study revealed that
the median time from sexual debut to first detection of
HPV was only three months and the 3-year cumulative risk
of acquiring cervical HPV was 46% (Figure 1).
Although the risk of HPV infection remains high through-
out a woman' s life, the highest risk is in adolescents
between the ages of 15---19 years. A study of HPV-negative
Colombian women 15---85 years of age with normal cer-
vical cytology at baseline clearly showed that, for any
HPV infection, the highest 5-year cumulative risk occurred
among women 15---19 years of age (42.5%) and thereafter
decreased with age, with women 45 years of age and older
having the lowest risk (12.4%).33
A majority of episodes of a type-specific HPV infec-
tion spontaneously resolve within 2 years but many young
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women may become infected with a new HPV type.34 In
a cohort of adolescent women followed closely over a
2.2-year period, the median duration of persistence of a
specific HPV type was 168 days, but high risk oncogenic
HPV types were more persistent than low risk types (P =
0.034).35 Persistence of infection is an important clinical
consideration because this is the major risk factor for
malignant transformation of cervical cells.
HPV transmission
HPV transmission almost exclusively occurs following skin-
to-skin contact with an infected partner. Sexual intercourse
is not strictly necessary and the virus can also be trans-
mitted during sexual foreplay including fingers.15 To date,
there is little or no evidence to suggest that HPV can
be transmitted by nonsexual routes (that is, environ-
mental transmission). HPV is exclusively an intraepithelial
pathogen and is unable to propagate in cell culture. HPV
can only replicate in stratified squamous epithelium and,
to do so, exploits the natural differentiation program of
basal keratinocytes. As a result of microabrasions or tears
that can occur during sexual activity, HPV penetrates and
infects the basal keratinocytes of the epithelium, where it
may persist in a latent state. As the basal cells differenti-
ate and mature, the HPV genome is replicated episomally
with the aid of two HPV nonstructural proteins (E1 and
E2). Other nonstructural proteins (E6 and E7) are then ex-
pressed, which delay the natural maturation of epithelial
cells in order to exploit the host cell' s DNA machinery
to synthesize the structural proteins (L1 and L2) needed
for viral assembly. As a result of E6 and E7 disrupting
cell division, infected epithelial cells out grow noninfected
cells and give rise to dysplasia, warts, or tumors. The
entire process eventually results in the release of new
virus particles (virus-laden squames or koilocytes) to the
epithelial surface. The shedding of koilocytes serves as the
vector of HPV transmission, with each koilocyte containing
approximately 50---100 virions.
The normal cervix may be particularly vulnerable to
HPV infection during periods of squamous metaplasia (e.g.,
Figure 2 High-risk types of HPV have been identified in a wide range of malignancies.
during early adolescence and first pregnancy) when large
regions of rapidly proliferating cells occur.15,36 Infection of
the cervix with high-risk HPV types (e.g., 16 and 18) re-
solves spontaneously in many patients probably through the
actions of the immune system. However, in some patients
who are persistently infected by the virus, the HPV genome
can become integrated into the DNA of the host cells,
leading to precancerous and subsequent cancerous changes
resulting from interference with the normal control of the
cell growth cycle.36
World burden of HPV-related disease
Genital HPV infections are associated with a wide spec-
trum of disease. Most patients with cervical HPV infection,
approximately 300 million cases worldwide annually,9 are
typically never seen in a gynecology practice because the
HPV infections do not lead to any detectable cytologic
abnormalities and clear spontaneously or because there is
no access to care. An important subset of these patients
subsequently progress to low- and high-grade cervical dys-
plasia (30 million and 10 million cases, respectively), and
eventually cervical cancer (0.5 million cases).9 After breast
cancer, cervical cancer is the most frequent cancer in
women 15---44 years of age in Europe.37 HPV 16 and 18 are
responsible for a majority of cervical cancers worldwide
and can also give rise to low- and high-grade cervical
lesions (CIN 1, 2, 3).21
In addition to cervical cancer, high-risk HPV is also
associated with approximately 50% or more of vaginal,
vulvar, and penile carcinomas; ∼85% of anal carcinomas;
and 10% of cancers of the larynx and aerodigestive tract
(Figure 2).9,38- 40 In addition, approximately 20% of oropha-
ryngeal cancers contain HPV DNA.40 Many of these cancers
are preceded by HPV-associated dysplastic lesions, includ-
ing vulvar intraepithelial neoplasia (VIN), vaginal intraep-
ithelial neoplasia (VaIN), penile intraepithelial neoplasia
(PIN), anal intraepithelial neoplasia (AIN), or perianal
intraepithelial neoplasia (PAIN).
The rate of VIN has been increasing worldwide and in
the United States, particularly in younger women, a trend
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Table 1 Despite well established screening programs in many European countries, cervical cancer continues to occur
Country Recommendation % Regularly Cervical cancer Cervical cancer
screened mortality/100,000 incidence/100,000
Age range (yrs) Interval (yrs)
Finland 30---60 5 93 3.0 6.2
England 25---64 3---5 83 5.1 10.5
Sweden 23---60 3 83 5.6 10.9
Belgium 25---64 3 78 6.2 12.8
The Netherlands 30---60 5 77 3.8 9.4
Denmark 23---59 3 75 8.6 16.3
France 25---65 3 69 5.4 13.6
Italy 25---64 3 53---74 4.0 11.6
Germany 20---85 1 50 7.1 14.7
Spain 25---65 3 27 3.6 10.3
US 21---30 1 79 2.5 8.7
(for comparison) >30 2---3
Data obtained from Anttila A, Ronco G, Clifford G, et al. Br J Cancer. 2004;91:935---94161; van Ballegooijen M, van den Akker-van Marle
E, Patnick J, et al. Eur J Cancer. 2000;36:2177---218862; Ferlay J, Bray F, Pisani P, Parkin DM. Lyon, France: IARC Press; 200437; US
Department of Health and Human Services. Healthy People 2010. Vol. 1---2, 2nd edition. Washington, DC: US Government Printing
Office: 2000. (Level III)63; Clinical Management Guidelines for Obstetrician-Gynecologists. ACOG Practice Bulletin
2003;102:417---42764; Clinical US Cancer Statistics Working Group. United States Cancer Statistics: 2002 Incidence and Mortality.
Atlanta: US Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute65.
that appears to be associated with HPV infection.41,42 For
example, in the United States over the period 1973 to
1987, the rate of VIN 3 doubled (from 1.1 to 2.1 per
100,000 women-years), exceeding the rate of invasive vul-
var cancer.42 HPV 16 appears to be the dominant HPV type
associated with high-grade VIN, followed by HPV 18.43,44
It is important to note that a clinically important
segment of the overall burden of HPV disease is associ-
ated with nononcogenic HPV 6 and 11. These two HPV
types are not only associated with low grade cervical
lesions and anogenital warts but also cutaneous lesions,
and respiratory papillomatosis.45,46 In addition, the clinical
consequences of HPV 6 and 11 infections tend to become
manifest more rapidly compared with high-risk HPV types
--- for example, incident HPV 6 and 11 invections can give
rise to genital warts over a time frame considerably shorter
than the time from first HPV infection to high-grade CIN.47
Genital warts are almost exclusively caused by HPV 6 and
11,48 are extremely contagious,49and result in a high level
of emotional distress and anxiety.12,50- 52 Available chemi-
cal, immune enhancing, or surgical ablative treatments for
genital warts are often followed by recurrences and are
costly and painful.53
Cervical cancer --- continued occurrence
despite screening programs
Cellular atypia of the cervix can only be accurately
detected by cytopathological analysis of the cervical ep-
ithelium. The gold standard for identifying precancerous
cervical dysplasia is the Pap smear, introduced over 50
years ago. This cheap, noninvasive test is the founda-
tion for effective early detection and evidenced-based
therapeutic interventions.
Although wide variation exists in screening policies
among European countries,54 there is sound clinical ev-
idence demonstrating the effectiveness of cytological
screening in preventing cervical cancer. In Finland, cer-
vical cancer incidence and mortality rates (tracked by
the Finnish Cancer Registry since 1953) abruptly declined
after 1962 following the introduction of a cervical cancer
screening program. However, in Finland, as in many other
European countries, cervical cancer has not been erad-
icated and continues to represent a considerable public
health challenge despite established screening programs
(Table 1).
It is important to appreciate that for every case of in-
vasive cancer detected by cytological screening, there are
many more women with precancerous lesions or atypical
squamous cells of undetermined significance (ASC-US).55
These cases require careful long-term follow-up, multiple
clinic visits, often evaluation by colposcopy and biopsy, and
an adequate infrastructure to process and analyze cervical
specimens.55,56 Thus, while evaluation and management of
HPV-associated cytologic abnormalities has markedly re-
duced cervical cancer rates, it is extremely costly, placing
an enormous burden on the healthcare system. In the
United States, the direct HPV-attributable medical costs
of evaluating abnormal cervical cytology and subsequent
treatment of related neoplasias has been estimated to
be $3.4 billion annually among women of all ages.57 Fur-
thermore, it should also be pointed out that one of the
most frequent reasons for medical malpractice litigation
in the US is false negative Pap smears in women with
HPV-associated precancerous lesions.55
Treatment of CIN is also not without deleterious long-
term consequences for some patients, increasing both risk
of cervical and other cancers.58 A recent Finnish study
assessing the 20-year risk of cervical and other cancers in
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women treated for CIN showed that surgical treatment of
CIN was associated with an increase in the standardized
incidence ratio (ratio of observed to expected number of
cases) of cancer of the cervix (2.8, 95% confidence interval
[CI] 1.7---4.2), vulva (4.1 95% CI 1.5---8.9), vagina (12.0, 95%
CI 3.9---28), and anus (5.7, 95% CI 1.2---17).58
A recent meta-analysis of 27 studies indicates that
treatment of young women with mild cervical abnormali-
ties using excisional procedures may increase the risk of
subsequent adverse pregnancy outcome.59 Surgical removal
of intraepithelial lesion by techniques such as CO2 laser
excision, large loop excision of the transformation zone
(LLETZ), loop electrosurgical excision procedure (LEEP),
or cold-knife conization were all associated with varying
negative effects on preterm delivery, low birthweight,
need for caesarean section, and premature rupture of the
membranes. As a result of these findings, the authors
recommended caution in the treatment of young women
with mild cervical abnormalities.
Conclusions
HPV infections are highly prevalent, especially in adoles-
cent women between the ages of 15---19 years, resulting
in an enormous burden of disease worldwide. Although
many HPV infections clear spontaneously without any in-
tervention, persistent infection with oncogenic HPV types
increases the risk for a wide range of genital neoplasias,
including cervical, vulvar, vaginal, and penile cancers. In
addition, nononcogenic HPV 6 and 11 types contribute to
the overall burden of HPV disease, giving rise to anogen-
ital warts, low-grade Pap smear atypias, and respiratory
papillomatosis (rare). Although an effective tool in reduc-
ing the incidence of cervical cancer, cytological screening
techniques have not eradicated this disease. Importantly,
cervical screening programs are not available in developing
countries where more than 80% of cervical cancer cases
occur.60 Furthermore, the evaluation and management of
HPV-associated cytologic abnormalities is costly, drains
health care resources, and increases the risk for adverse
pregnancy outcome.
A prophylactic quadrivalent HPV vaccine is now avail-
able that induces the formation of virus-neutralizing an-
tibodies, preventing HPV infection with the virus types
contained in the vaccine. Universal immunization with
a quadrivalent HPV vaccine can be expected to have a
substantial impact on the overall burden of HPV-related
genital diseases and may actually herald the beginning of
the end of cervical cancer.
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